The Danish Medicines Agency to strengthen its leadership and professional focus

A new division with medical expertise and a general strengthening of the leadership throughout the Agency. This is the essence of the organisational change which will take effect in the Danish Medicines Agency at the turn of the year.

”We are undergoing a major transformation at the Danish Medicines Agency, and in this connection we will change the organisation so that we have the optimal organisational framework needed to realise our vision of a Danish Medicines Agency in European top class,” says Director General Thomas Senderovitz.

One of the most significant changes will be the creation of a new division: Medical Evaluation & Biostatistics. This division will gather the doctors from the licensing and pharmacovigilance divisions, engaging in marketing authorisations before and after the initial authorisation. The purpose of the new division is to create the critical mass in the area needed to make evaluations of authorisations and adverse reactions as well as overall evaluations of benefit/risk analyses for the benefit of the entire Agency.

”The division will be made up of highly professional resources, and the vacant position as director of the division will be posted shortly. In addition to the creation of the new division, we will strengthen our leadership by the appointment of a number of new team leaders in some of our large units. We will also establish cross-functional committees – including a committee for medicinal products – to ensure transparent decision-making processes for our cross-cutting tasks.”

”I am convinced that the organisational change will contribute to an overall strengthening of the Danish Medicines Agency’s work to ensure the availability of effective, safe and accessible medicines, because we create a better framework for knowledge sharing and for more effective procedures,” says Thomas Senderovitz.

The organisational change will become effective on 1 January 2017.